BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38463353)

  • 1. Correlation between serum markers and transjugular intrahepatic portosystemic shunt prognosis in patients with cirrhotic ascites.
    Hu XG; Yang XX; Lu J; Li G; Dai JJ; Wang JM; Deng Y; Feng R
    World J Gastrointest Surg; 2024 Feb; 16(2):481-490. PubMed ID: 38463353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [MELD score in prediction of early mortality in patients suffering refractory ascites treated by TIPS].
    Fejfar T; Safka V; Hůlek P; Vanásek T; Krajina A; Jirkovský V
    Vnitr Lek; 2006 Sep; 52(9):771-6. PubMed ID: 17091599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt.
    Angermayr B; Cejna M; Karnel F; Gschwantler M; Koenig F; Pidlich J; Mendel H; Pichler L; Wichlas M; Kreil A; Schmid M; Ferlitsch A; Lipinski E; Brunner H; Lammer J; Ferenci P; Gangl A; Peck-Radosavljevic M
    Gut; 2003 Jun; 52(6):879-85. PubMed ID: 12740346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian network-based survival prediction model for patients having undergone post-transjugular intrahepatic portosystemic shunt for portal hypertension.
    Chen R; Luo L; Zhang YZ; Liu Z; Liu AL; Zhang YW
    World J Gastroenterol; 2024 Apr; 30(13):1859-1870. PubMed ID: 38659484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of mortality after emergent transjugular intrahepatic portosystemic shunt placement: use of APACHE II, Child-Pugh and MELD scores in Asian patients with refractory variceal hemorrhage.
    Tzeng WS; Wu RH; Lin CY; Chen JJ; Sheu MJ; Koay LB; Lee C
    Korean J Radiol; 2009; 10(5):481-9. PubMed ID: 19721833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Patient Survival with Psoas Muscle Density Following Transjugular Intrahepatic Portosystemic Shunts: A Retrospective Cohort Study.
    Zhang B; Cai W; Gao F; Lin X; Qian T; Gu K; Song B; Chen T
    Med Sci Monit; 2022 Jan; 28():e934057. PubMed ID: 35031594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision making for transjugular intrahepatic portosystemic stent shunt in refractory ascites and variceal bleeding: MELD, or not MELD, that is the question.
    Pitton MB; Zimmermann T; Mildenberger P; Weinmann A; Kloeckner R; Düber C; Mittler J; Hoppe-Lotichius M; Otto G
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e214-e222. PubMed ID: 33230020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validating the prognostic value of Freiburg index of posttransjugular intrahepatic portosystemic shunt survival score and classic scores in Chinese patients with implantation of transjugular intrahepatic portosystemic shunt.
    Song J; Wang X; Yan Y; Xiang T; Luo X
    Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1074-1080. PubMed ID: 36062497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.
    Bettinger D; Sturm L; Pfaff L; Hahn F; Kloeckner R; Volkwein L; Praktiknjo M; Lv Y; Han G; Huber JP; Boettler T; Reincke M; Klinger C; Caca K; Heinzow H; Seifert LL; Weiss KH; Rupp C; Piecha F; Kluwe J; Zipprich A; Luxenburger H; Neumann-Haefelin C; Schmidt A; Jansen C; Meyer C; Uschner FE; Brol MJ; Trebicka J; Rössle M; Thimme R; Schultheiss M
    J Hepatol; 2021 Jun; 74(6):1362-1372. PubMed ID: 33508376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying the original model for end-stage liver disease score rather than the model for end-stage liver disease-Na score for risk stratification prior to transjugular intrahepatic portosystemic shunt procedures.
    Lee BT; Yang AH; Urban S; Kim KY; Ter-Oganesyan R; Yuan L; Han HH; Khemichian S; Kahn JA; Kim B
    Eur J Gastroenterol Hepatol; 2021 Apr; 33(4):541-546. PubMed ID: 32398491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Liver Failure after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis with Model for End-Stage Liver Disease Score of 12 or Less: Incidence, Outcome, and Prognostic Factors.
    Luca A; Miraglia R; Maruzzelli L; D'Amico M; Tuzzolino F
    Radiology; 2016 Aug; 280(2):622-9. PubMed ID: 26982564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience.
    Lodato F; Berzigotti A; Lisotti A; Azzaroli F; Mosconi C; Giampalma E; Renzulli M; Cappelli A; Buonfiglioli F; Calvanese C; Zoli M; Golfieri R; Mazzella G
    Scand J Gastroenterol; 2012 Dec; 47(12):1494-500. PubMed ID: 22958120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation.
    Ronald J; Wang Q; Choi SS; Suhocki PV; Hall MD; Smith TP; Kim CY
    Diagn Interv Imaging; 2018 Mar; 99(3):163-168. PubMed ID: 29154015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of model performance to predict survival after transjugular intrahepatic portosystemic shunt placement.
    Allegretti AS; Frenk NE; Li DK; Seethapathy H; Vela Parada XF; Long J; Endres P; Pratt DS; Chung RT; Ganguli S; Irani Z; Yamada K
    PLoS One; 2019; 14(5):e0217442. PubMed ID: 31120995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.
    Wang Z; Wu YF; Yue ZD; Zhao HW; Wang L; Fan ZH; Zhang Y; Liu FQ
    World J Gastroenterol; 2021 Feb; 27(5):416-427. PubMed ID: 33584073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inclusion of sarcopenia improves the prognostic value of MELD score in patients after transjugular intrahepatic portosystemic shunt.
    Bai YW; Liu JC; Yang CT; Wang YL; Wang CY; Ju SG; Zhou C; Huang SJ; Li TQ; Chen Y; Yao W; Xiong B
    Eur J Gastroenterol Hepatol; 2022 Sep; 34(9):948-955. PubMed ID: 35594511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Model for End-Stage Liver Disease (MELD) and Sarcopenia predicts mortality after transjugular intrahepatic portosystemic shunt (TIPS).
    Delgado MG; Mertineit N; Bosch J; Baumgartner I; Berzigotti A
    Dig Liver Dis; 2024 Mar; ():. PubMed ID: 38555198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlling nutritional status score as a new indicator of overt hepatic encephalopathy in cirrhotic patients following transjugular intrahepatic portosystemic shunt.
    Li J; Feng D; Pang N; Zhao C; Gao L; Liu S; Li L
    Clin Nutr; 2022 Feb; 41(2):560-566. PubMed ID: 35032860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covered stents are better than uncovered stents for transjugular intrahepatic portosystemic shunts in cirrhotic patients with refractory ascites: a retrospective cohort study.
    Maleux G; Perez-Gutierrez NA; Evrard S; Mroue A; Le Moine O; Laleman W; Nevens F
    Acta Gastroenterol Belg; 2010; 73(3):336-41. PubMed ID: 21086935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transjugular Intrahepatic Porto-Systemic Shunt in Patients with Liver Cirrhosis and Model for End-Stage Liver Disease ≥15.
    Ascha M; Hanouneh M; S Ascha M; Zein NN; Sands M; Lopez R; Hanouneh IA
    Dig Dis Sci; 2017 Feb; 62(2):534-542. PubMed ID: 27154510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.